CARGO Therapeutics (CRGX) Projected to Post Quarterly Earnings on Tuesday

CARGO Therapeutics (NASDAQ:CRGX) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

CARGO Therapeutics Stock Down 2.4%

Shares of NASDAQ CRGX opened at $4.02 on Monday. The firm’s 50-day moving average price is $4.21 and its 200-day moving average price is $9.89. The company has a market cap of $185.36 million, a PE ratio of -0.94 and a beta of 0.47. CARGO Therapeutics has a 52-week low of $3.00 and a 52-week high of $25.45.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CRGX shares. JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, January 30th. Truist Financial downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $32.00 to $7.00 in a report on Thursday, January 30th. HC Wainwright cut shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. William Blair cut shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 30th. Finally, Jefferies Financial Group cut shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $3.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, CARGO Therapeutics currently has a consensus rating of “Hold” and an average target price of $15.00.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.